PIK3CG and prostate carcinoma: There is an opinion shared by a number of researchers that many prostate cancers, in particular those with deregulated signaling pathways such as PI3K, should be treated with investigational therapies that target not only AR but these signaling pathways as well [131] or with differentiation inducing therapies [132].